Spravato

Learn Spravato Coding & Reimbursement Now!

Learn Spravato Coding & Reimbursement Now! Navigating the coverage and reimbursement landscape for SPRAVATO® (esketamine) nasal spray requires careful consideration to ensure compliance and optimize reimbursement. The assignment of a Healthcare Common Procedure Coding System (HCPCS) code and a payment rate does not guarantee coverage by Medicare, Medicaid, or private payers. Each payer determines whether […]

Learn Spravato Coding & Reimbursement Now! Read More »

Why Ensuring Payer Contracting for Buy-and-Bill Is Essential Before Implementing Spravato® in Your Practice

Why Ensuring Payer Contracting for Buy-and-Bill Is Essential Before Implementing Spravato® in Your Practice Before adopting the buy-and-bill model for Spravato® (esketamine) nasal spray in your practice, it’s crucial to confirm that the payers in your network are contracted to support this billing method. This step ensures financial sustainability, smooth reimbursement, and optimal patient care.

Why Ensuring Payer Contracting for Buy-and-Bill Is Essential Before Implementing Spravato® in Your Practice Read More »

Understanding the Differences Between Buy-and-Bill and Assignment of Benefits for Spravato® (Esketamine)

Understanding the Differences Between Buy-and-Bill and Assignment of Benefits for Spravato® (Esketamine) Spravato® (esketamine) nasal spray is a groundbreaking treatment for treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation or behavior. As its use grows, healthcare providers and patients must navigate different payment models to access the medication. Two common billing

Understanding the Differences Between Buy-and-Bill and Assignment of Benefits for Spravato® (Esketamine) Read More »

Rising Mental Health Concerns: Insights from the 2024 CVS Health Survey

Rising Mental Health Concerns: Insights from the 2024 CVS Health Survey A comprehensive survey conducted by CVS Health in collaboration with Morning Consult reveals a significant escalation in mental health concerns among Americans. The survey highlights that 65% of adults are now concerned about their own or their loved ones’ mental health, reflecting a 6%

Rising Mental Health Concerns: Insights from the 2024 CVS Health Survey Read More »

Breaking Barriers: Companies Explore Psychedelic Therapy Coverage for Employees

Breaking Barriers: Companies Explore Psychedelic Therapy Coverage for Employees In recent years, there has been a notable shift in the corporate world’s approach to mental health care. Companies are increasingly exploring innovative methods to support employee well-being, with a particular focus on psychedelic drug therapy. According to a report by the New York Post published

Breaking Barriers: Companies Explore Psychedelic Therapy Coverage for Employees Read More »